Recent Headlines
Within Biotechnology

Valis Corporation Technology Used in Large Brain Model Project

Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.

Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100

Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.

Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group

ALS Therapy Development Institute Commemorates 25th Anniversary at the Leadership Weekend in October

Taking place from October 3-5, 2024, in the Boston area, ALS TDI’s Leadership Weekend features a series of community-focused events, including an Open House at ALS TDI’s cutting-edge research lab, the ALS TDI Research Summit, and the White Coat Affair gala. - September 03, 2024 - ALS Therapy Development Institute

New Partnership: Luminoso and KAPS Group

We are delighted to announce the partnership agreement between the KAPS Group, a long-time leader in text analytics/semantic AI consulting services for enterprise data-driven solutions, and Luminoso, a leading sentiment analysis company, whose Daylight software, a powerful but easy to use sentiment analysis tool. - August 29, 2024 - KAPS Group

ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies

New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd

Huntington Study Group Announces New CEO

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group

Guides Collective Steps in Where Traditional Therapies have Failed with a Concierge Service to Match Seekers with Psychedelic Guides

Guides Collective launches psychedelic concierge service poised to become the "BetterHelp" of the psychedelic space. With over 600+ qualified psychedelic guides in their network, they work with you to find a psychedelic modality catered to a persons specific needs and desired outcome. - August 14, 2024 - Guides Collective

Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical

New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.

Minus K Technology Announces Its Ninth Educational Giveaway of Vibration Isolators to U.S. Colleges and Universities

Minus K Technology announces its Educational Giveaway of Vibrations Isolators to U.S. Colleges and Universities. - August 05, 2024 - Minus K Technology Inc.

Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing

Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.

Edison Agrosciences Announces $600,000 Seed Financing Round and Addition of Industry Veteran Tom Marsh to Board of Directors

Edison Agrosciences, an industrial biomaterials company developing a sustainable domestic source of natural rubber from sunflowers, today announced the closing of a $600,000 seed financing. - July 26, 2024 - Edison Agrosciences

Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment

Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years

U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process

U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.

MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy

Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics

SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board

SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx

Huntington Study Group Announces Launch of LEAD-HD Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group

NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada

NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics

Abel Womack CEO Announces His Retirement and Successor

After 50 years with Abel Womack, John Croce, CEO retires. - June 27, 2024 - Abel Womack Inc

Daicel Arbor Biosciences Launches New myTXTL® Kits to Accelerate Protein Expression

Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering. These powerful new kits include the myTXTL Pro Kit and the myTXTL Antibody/DS... - June 27, 2024 - Daicel Arbor Biosciences

SYNAPS Dx Announces Expansion to New, State-of-the-Art Facility

SYNAPS Dx has moved to a new, state-of-the-art facility in Rockville, MD, to meet growing demand and enhance patient care. The larger space and advanced infrastructure will support more diagnostic samples and ensure timely, accurate Alzheimer's and dementia diagnoses. Fully qualified for high-complexity clinical lab testing, the facility boosts diagnostic capabilities. The expansion will also advance the DISCERN™ test, a minimally invasive tool distinguishing Alzheimer's from other dementias. - June 26, 2024 - SynapsDx

Cambridge Polymer Group Unveils Restructure to Accelerate Client Innovation through Material Science

Cambridge Polymer Group (CPG) announced a new leadership structure to better support clients in developing innovative products. CPG is creating a new five-person senior management team with deep materials science expertise, which will allow for closer collaboration with clients on complex projects. Dr. Gavin Braithwaite will be the new CEO and Dr. Stephen Spiegelberg will move to the new role of Chief Scientific Officer (CSO). - June 23, 2024 - Cambridge Polymer Group

KIRON.AI Launches Book “NEOBANK Navigating the Future of Banking” by Author and Bank Owner Ronald Ingram

KIRON.AI, a Henderson, Nevada-based AI Health & Wealth company launches “NEOBANK Navigating the Future of Banking,” a groundbreaking book exposing the history and predicting the future of banking from author Ronald Ingram’s perspective as a bank owner, historian, futurist and polymath. The company KIRON.AI employs artificial intelligence (AI) to discover, uncover, develop and deploy protocols, tools and information to enhance human wealth and health preservation and generation. - June 11, 2024 - Kiron.AI

Groundbreaking Study Shows Promise in AAV9 Gene Therapy for FOXG1 Syndrome; Rescue of Brain Structure Abnormalities and Deficits.

New publication shows groundbreaking result in FOXG1 AAV9 gene therapy studies, rescuing structural brain abnormalities caused by the pediatric rare disease, FOXG1 syndrome. This paper summarizing work done by the FOXG1 Research Center, led by Dr. Soo-Kyung Lee, Dr. Jae W. Lee and Dr. Kathrin Meyer (responsible for the SMA gene therapy), shows remarkable rescue of brain abnormalities using AAV9 gene therapy. - June 10, 2024 - FOXG1 Research Foundation

Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company

FlowSense: Affordable Antibiotic Testing to Transform the Honey Industry from Biorex Food Diagnostics

Biorex Food Diagnostics announced today the launch of its cutting-edge FlowSense product line, with the first phase designed specifically for the honey industry. The new FlowSense test products introduce a comprehensive range of antibiotic test panels, providing honey producers with an innovative... - June 07, 2024 - Biorex Food Diagnostics

Limited Opportunity: Enroll in Ales for ALS 2024 Today, Secure Your Spot as Part of a Growing National Movement

Ales for ALS invites brewers to craft distinctive and flavorful beers using a custom hop blend generously donated by Yakima Chief Hops. In exchange, participating brewers pledge to donate $1 for every pint sold, directly contributing to groundbreaking ALS research at the ALS Therapy Development Institute (ALS TDI). - May 04, 2024 - ALS Therapy Development Institute

Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease

AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu

No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption

Thar Process, with 34 years of expertise in supercritical fluid extraction, has developed a sustainable way to produce de-fatted lecithin powder that has less oil and longer shelf-life stability. The new process is semi-continuous and sustainable because it utilizes upcycled CO2 from waste sources instead of using toxic acetone which is the industry standard. - April 26, 2024 - Thar Process

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024 - ALPCO

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.

Huntington Study Group Launches Project AWARE 2.0 Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group

Minus K Congratulates to the Winners of Their 2023/2024 Educational Giveaway

Minus K congratulates the four winners of the Minus K's 2023/2024 Educational Giveaway. Over $75,000 of new passive mechanical hub hertz vibration isolators have been granted to universities and colleges in the U.S. over the last ten years. - April 10, 2024 - Minus K Technology Inc.

FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.

Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology

The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq

MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.

Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer

Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. - March 11, 2024 - Defined Bioscience Inc.

ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials

The ALS Therapy Development Insitute (ALS TDI) has announced the beta launch of the ALS Trial Navigator. This innovative set of tools is designed to guide people with ALS and caregivers through the process of finding and understanding ALS clinical trials – with the ultimate goal of personalizing the search process and helping users make informed decisions about participation in trials. - February 29, 2024 - ALS Therapy Development Institute

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer

Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.

Flow Circuits and Rapid Fluidics Ltd. Announce Partnership to Drive Microfluidic Innovation

Flow Circuits design platform and Rapid Fluidics 3D Print capabilities perfectly complement each other for rapid fluidic system development. Combined they empower researchers in diverse markets such as Pharmaceutical & Life Sciences Research, Point of Care Testing and Clinical Diagnostics, and Environment and Industrial Analytics. - February 05, 2024 - Rapid Fluidics Ltd

Recent Headlines Within Biotechnology

Recent Headlines
Within Biotechnology